Five‐year Survival Follow‐up of a Phase III Randomised Trial Comparing Ofatumumab Versus Physicians' Choice for Bulky Fludarabine‐refractory Chronic Lymphocytic Leukaemia: A Short Report
British Journal of Haematology - United Kingdom
doi 10.1111/bjh.16429
Full Text
Open PDFAbstract
Available in full text
Categories
Date
January 28, 2020
Authors
Publisher
Wiley